Economic effects of clinical pharmacy interventions: A literature review

American Journal of Health-System Pharmacy

Volumn 65, Issue 12, 2008, Pages 1161-1172

  De Rijdt, Thomas ^a   Willems, Ludo ^a,b   Simoens, Steven ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Clinical pharmacists; Clinical pharmacy; Interventions; Methodology; Pharmaceutical services; Pharmacoeconomics; Research

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PHARMACY; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITAL PHARMACY; HUMAN; MEDICAL LITERATURE; MEDICATION ERROR; METHODOLOGY; PHARMACIST ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 45749088618     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070506     Document Type: Article

References (39)

1. Hepler CD. The third wave in pharmaceutical education: the clinical movement. Am J Pharm Educ. 1987; 51:369-85.
2. European Society of Clinical Pharmacy. What is clinical pharmacy? www.escpweb.org/site/cms/contentViewArticle.asp?article=1712 (accessed 2007 Sep 3).
3. American College of Clinical Pharmacy. Clinical pharmacy defined. www.accp.com/clinical_pharmacy.php (accessed 2007 Sep 3).
4. Kaboli PJ, Hoth AB, McClimon BJ et al. Clinical pharmacists and inpatient medical care. A systematic review. Arch Intern Med. 2006; 166:955-64.
5. Schumock GT, Meek PD, Ploetz PA et al. Economic evaluations of clinical pharmacy services: 1988-1995. Pharmacotherapy. 1996; 16:1188-208.
6. Willett MS, Bertch KE, Rich DS et al. Prospectus on the economic value of clinical pharmacy services: a position statement of the American College of Clinical Pharmacy. Pharmacotherapy. 1989; 9:45-56.
7. Kopp BJ, Mrsan M, Erstad BL et al. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health-Syst Pharm. 2007; 64:2483-7.
8. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patients. Am J Health-Syst Pharm. 2007; 64:1935-42.
9. Haumschild MJ, Karfonta TL, Haumschild MS et al. Clinical and economic outcomes of a fall-focused pharmaceutical intervention program. Am J Health-Syst Pharm. 2003; 60:1029-32.
10. Finley PR, Rens HR, Pont JT et al. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health-Syst Pharm. 59:1518-26.
11. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, England: Oxford Univ. Press; 2005:103-246.
12. McMullin ST, Hennenfent JA, Ritchie DJ et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999; 159:2306-9.
13. Baldinger SL, Chow MS, Gannon RH et al. Cost savings from having a clinical pharmacist work part-time in a medical intensive care unit. Am J Health-Syst Pharm. 1997; 54:2811-4.
14. Gandhi PJ, Smith BS, Tataronis GR et al. Impact of a pharmacist on drug costs in a coronary care unit. Am J Health-Syst Pharm. 2001; 58:497-503.
15. Boyko WL Jr, Yurkowski PJ, Ivey MF et al. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health-Syst Pharm. 1997; 54:1591-5.
16. Olson LM, Desai S, Soto ML. Evaluation of pharmacists' interventions at a university teaching hospital. Can J Hosp Pharm. 2005; 58:20-5.
17. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 281:267-70. [Erratum, JAMA. 2000; 283:1293.]
18. Kucukarslan SN, Peters M, Mlynarek M et al. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003; 163:2014-8.
19. Van den Bemt PM, Postma MJ, van Roon EN et al. Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff. Drug Saf. 2002; 25:135-43.
20. Fraser GL, Stogsdill P, Dickens JD et al. Antibiotic optimization: an evaluation of patient safety and economic outcomes. Arch Intern Med. 1997; 157:1689-94.
21. Gums JG, Yancey RW, Hamilton CA et al. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy. 1999; 19:1369-77.
22. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacistmanaged aminoglycoside or vancomycin therapy. Am J Health-Syst Pharm. 2005; 62:1596-605.
23. Halley HJ. Approaches to drug therapy, formulary and pathway management in a large community hospital. Am J Health-Syst Pharm. 2000; 57(suppl 3):S17-21.
24. Bailey TC, Ritchie DJ, McMullin ST et al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy. 1997; 17:277-81.
25. Gentry CA, Greenfield RA, Slater LN et al. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health-Syst Pharm. 2000; 57:268-74.
26. Zaidi ST, Hassan Y, Postma MJ et al. Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital. Pharm World Sci. 2003; 25:299-302.
27. Krupicka MI, Bratton SL, Sonnenthal K et al. Impact of a pediatric clinical pharmacist in the pediatric intensive care unit. Crit Care Med. 2002; 30:919-21.
28. Nesbit TW, Shermock KM, Bobek M et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health-Syst Pharm. 2001; 58:784-90.
29. Mutnick AH, Sterba KJ, Peroutka JA et al. Cost savings and avoidance from clinical interventions. Am J Health-Syst Pharm. 1997; 54:392-6.
30. Wilson AF, Foral PA, Nystrom KK et al. A review of clinical pharmacy interventions prior to implementation of a personal digital assistant intervention program in a community hospital. Hosp Pharm. 2003; 38:1047-51.
31. Dooley MJ, Allen KM, Doecke CJ et al. A prospective multicenter study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. Br J Clin Pharmacol. 2003; 57:513-21.
32. Lada P, Delgado G Jr. Documentation of pharmacists' interventions in an emergency department and associated cost avoidance. Am J Health-Syst Pharm. 2007; 64:63-8.
33. Allenet B, Bedouch P, Rose F et al. Validation of an instrument for the documentation of clinical pharmacists' interventions. Pharm World Sci. 2006; 28:181-8.
34. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002; 22:134-47.
35. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007; 27:481-93.
36. Lee AJ, Boro MS, Knapp KK et al. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health-Syst Pharm. 2002; 59:2070-7.
37. Brennan TA, Leape LL, Laird NM et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991; 324:370-6.
38. Leape LL, Brennan TA, Laird NM et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
39. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002; 23:377-401.